-

Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course: Navigate CIS Pharmaceutical Markets with Expert Guidance on Evolving Regulations (ONLINE EVENT: June 19-20, 2025) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course" training has been added to ResearchAndMarkets.com's offering.

This interactive course will guide you through national procedures as well as explore the implications of and updates on the Eurasian Union regulation. The focus of the programme is to offer practical advice in developing your regulatory strategy for product approval in these countries and you will get the full benefit of our trainer's experience and expertise in the region.

The pharmaceutical markets in Russia, the Eurasian Union and the CIS are of growing commercial importance and companies looking to take advantage of the opportunities available need to be fully up to date with the evolving regulatory landscape for human pharmaceuticals, including the potential for market access offered by the latest legislation.

Benefits of attending:

  • Understand the competitive landscape of the growing markets in the CIS region
  • Discover the essential information on the latest regulations and registration procedures in the Eurasian Customs Union
  • Discuss national requirements and guidance for drug approval in the core CIS markets of Russia, Kazakhstan, Belarus, Ukraine and Azerbaijan
  • Develop your CIS regional submission plan and place it within your global regulatory strategy
  • Gain practical advice from an industry expert working in the CIS region

Why you should attend

Attending this programme will:

  • Give you the full background to the CIS pharmaceutical market
  • Ensure that you understand all the implications of the latest regulations which will affect how you do business in the Eurasian Economic Union (EAEU)
  • Help clarify the document requirements and timelines of national procedures and EAEU registration procedures
  • Update you on the national regulations in Russia, Belarus, Kazakhstan, Ukraine and other CIS countries

Certifications:

  • CPD: 12 hours for your records
  • Certificate of completion

Who Should Attend:

This seminar will be of particular interest to all those who need to learn about successful marketing authorisation applications and regulatory compliance in this region. The seminar will be useful either as an introductory or refresher course.

Key Topics Covered:

Day 1

CIS - regional regulatory overview

  • CIS and Russia Market Overview
  • Market protection policies
  • CIS and Russia in regional and international Regulatory Harmonisation

Common regional requirements in CIS

  • Administrative data, translations, normative documents, samples, labelling, etc

Eurasian economic area

  • Countries current members of EAEU and EAEU Official bodies
  • History of EAEU, scope of products, available experience
  • Terms of transition period for medicines

Eurasian Regulations for Medicines

  • Overview of EAEU regulatory framework
  • Registration Procedures and Application Process
  • EAEU submission documents and data requirements
  • GMP inspections
  • PhV requirements

Day 2

Registration of Medicine in Russia

  • Regulatory authorities in Russia
  • Key regulations governing the registration process
  • Clinical trials

National Regulatory Procedures in Russia

  • Application dossier and data requirements
  • Post approval life cycle maintenance applications
  • Safety reporting and market surveillance
  • Price and reimbursement
  • Patent data protection

Registration in other EAEU countries

  • Kazakhstan, Belarus, Armenia, Kirgizstan

Registration in other CIS countries

  • EU sphere of influence: Ukraine, Moldova, Georgia
  • National procedures: Azerbaijan, Uzbekistan, Tajikistan, Turkmenistan

Workshop - CIS Regional Regulatory Strategy

Speakers:

Anna Harrington-Morozova

Scientific and Regulatory Director

Regem Consulting Ltd

Anna Harrington-Morozova is a regulatory, drug development and external relations professional with over 20 years' experience gained in regulatory authority, academia, clinical and industry environment. Anna graduated in Russia as a pharmacist. After working in the Russian Ministry of Health and the Clinical Pharmacology Department of Moscow Medical University Anna held regulatory and external relation positions in the pharmaceutical industry and CROs in Russia and the UK, including senior regulatory affairs posts in GSK, EISAI, ICON and PRA. Anna currently acts as a Scientific and Regulatory Director at Regem Consulting Ltd - a regulatory and drug development consultancy with a focus on global regulatory and drug development strategies, advocacy and registrations in emerging markets.

For more information about this training visit https://www.researchandmarkets.com/r/tkjre3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Insomnia Drugs Market Outlook 2026-2034: Trends, Shares, and Growth Analysis Featuring Merck & Co., Eisai Co., Viatris, Perrigo Co., Neurim Pharmaceuticals and More - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Insomnia Drug Market Outlook 2026-2034: Market Share, and Growth Analysis" has been added to ResearchAndMarkets.com's offering. The Insomnia Drug Market is projected to expand from USD 2.95 billion in 2025 to USD 4.62 billion by 2034, exhibiting a CAGR of 5.1%. Encompassing both prescription and OTC solutions, the market spans across various formulations designed to alleviate sleep-onset and sleep-maintenance issues. Key pharmacologic categories include non-benzodi...

Strategies to Succeed in the $5+ Billion Tourette Syndrome Drugs Market, 2026-2034 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Tourette Syndrome Drugs Market Outlook 2026-2034: Market Share, and Growth Analysis" has been added to ResearchAndMarkets.com's offering. The Tourette Syndrome Drugs Market is projected to witness significant expansion in the coming years, escalating from a valuation of USD 2.76 billion in 2025 to approximately USD 5.03 billion by 2034, with a notable CAGR of 6.9%. The market predominantly caters to the pharmacological management of tic disorders, inclusive of voca...

The Global Market for Low Power/High Efficiency AI Semiconductors, 2026-2036 - Neuromorphic Computing and In-Memory Architectures Pave the Way for AI Semiconductor Market Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "The Global Market for Low Power/High Efficiency AI Semiconductors 2026-2036" has been added to ResearchAndMarkets.com's offering. The market for low power/high efficiency AI semiconductors stands as a pivotal segment within the global semiconductor industry, distinguished by devices surpassing 10 TFLOPS/W in power efficiency. This sector deals with systems like neuromorphic computing, in-memory architectures, edge AI processors, and specialized neural units. Spanni...
Back to Newsroom